Vivus Inc (VVUS) 4.12 $VVUS
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.
Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
VIVUS Reports Second Quarter 2014 Financial Results
Marketwire - Fri Aug 08, 5:25AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update.
Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:45PM CDT
Emergent BioSolutions (EBS) is set to report second quarter 2014 results on Aug 7 after the market closes.
Will Horizon Pharma (HZNP) Earnings Miss Estimates in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:00PM CDT
Horizon Pharma (HZNP) is set to report second quarter 2014 results on Aug 7 before the market opens.
Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 3:35PM CDT
Mylan (MYL) is set to report second quarter 2014 results on Aug 7 before the market opens.
Technical Analysis on Pharma Equities -- Mylan, AVANIR Pharma, Horizon Pharma, VIVUS, and Auxilium Pharma
PR Newswire - Wed Aug 06, 8:10AM CDT
On Tuesday, August 5, 2014, the NASDAQ Composite ended at 4,352.84, down 0.71%, the Dow Jones Industrial Average declined 0.84%, to finish the day at 16,429.47, and the S&P 500 closed at 1,920.21, down 0.97%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health care Sector Index ended the day at 701.26, down 0.89%, while the index has advanced 4.26% in the previous three months. Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: ANVR), Horizon Pharma Inc. (NASDAQ: HZNP), VIVUS Inc. (NASDAQ: VVUS), and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free research on these five companies can be accessed at:
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Thu Jul 31, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results for the second quarter ended June 30, 2014 after the NASDAQ Market closes on Thursday, August 7, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.
Vivus Shares Down 40.9% Since SmarTrend's Sell Call (VVUS)
Comtex SmarTrend(R) - Wed Jul 30, 4:44PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 6 months, Vivus has returned 40.89% as of today's recent price of $5.11.
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Jim Cramer's 'Mad Money' Recap: High Hopes and Low-Expectation Stocks
at The Street - Tue Jul 15, 7:00PM CDT
Stick with companies where any good news will be met with big gains, Cramer says.
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.
Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
VIVUS Reports Second Quarter 2014 Financial Results
Marketwire - Fri Aug 08, 5:25AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update.
Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:45PM CDT
Emergent BioSolutions (EBS) is set to report second quarter 2014 results on Aug 7 after the market closes.
Will Horizon Pharma (HZNP) Earnings Miss Estimates in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:00PM CDT
Horizon Pharma (HZNP) is set to report second quarter 2014 results on Aug 7 before the market opens.
Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 3:35PM CDT
Mylan (MYL) is set to report second quarter 2014 results on Aug 7 before the market opens.
Technical Analysis on Pharma Equities -- Mylan, AVANIR Pharma, Horizon Pharma, VIVUS, and Auxilium Pharma
PR Newswire - Wed Aug 06, 8:10AM CDT
On Tuesday, August 5, 2014, the NASDAQ Composite ended at 4,352.84, down 0.71%, the Dow Jones Industrial Average declined 0.84%, to finish the day at 16,429.47, and the S&P 500 closed at 1,920.21, down 0.97%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health care Sector Index ended the day at 701.26, down 0.89%, while the index has advanced 4.26% in the previous three months. Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: ANVR), Horizon Pharma Inc. (NASDAQ: HZNP), VIVUS Inc. (NASDAQ: VVUS), and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free research on these five companies can be accessed at:
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Thu Jul 31, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results for the second quarter ended June 30, 2014 after the NASDAQ Market closes on Thursday, August 7, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.
Vivus Shares Down 40.9% Since SmarTrend's Sell Call (VVUS)
Comtex SmarTrend(R) - Wed Jul 30, 4:44PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 6 months, Vivus has returned 40.89% as of today's recent price of $5.11.
The Implications of Obesity as a Disability in Europe
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 19, 3:13PM CDT
If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena...
Jim Cramer's 'Mad Money' Recap: High Hopes and Low-Expectation Stocks
at The Street - Tue Jul 15, 7:00PM CDT
Stick with companies where any good news will be met with big gains, Cramer says.
